The Vanguard Group Discloses Position in Avadel Pharmaceuticals plc

The Vanguard Group, Inc. has released a Form 8.3 disclosure regarding its position in Avadel Pharmaceuticals plc. The disclosure follows Rule 8.3 of the Irish Takeover Panel Act, 1997. The disclosure date is December 22, 2025.

The key revelation is that The Vanguard Group owns 5,862,294 US$0.01 ordinary shares in Avadel Pharmaceuticals, representing a 6.02% interest. Additionally, the document reports a minor transaction where 760 shares were bought and 6,481 shares sold, both at $21.58 per unit.

There are no cash-settled or stock-settled derivative positions reported, and no other parties are involved in this disclosure. No agreements, arrangements, or understandings related to options or derivatives exist between the parties.